Talk to a hospital pharmacist long enough, and the conversation almost always kind of drifts into drug shortages. Not the sudden, crisis-level kind that makes the news. The quieter kind — a blood pressure medication on backorder for three months, an injectable that just stopped showing up from the usual supplier. That’s become normal. It probably shouldn’t be.
A lot of that has to trace back to one uncomfortable truth: the U.S. stopped making most of its own medicines a long time ago.
The U.S. Doesn’t Make Most of Its Own Drugs Anymore
People generally assume a country that spends this much on healthcare also controls where its medications come from. It doesnt, really — not at the ingredient level anyway.
In 2024, the U.S. imported over 828,000 metric tons of pharmaceutical goods, and if you zoom out a bit, back in 2000 that number was like around 118,000 metric tons. Americans didn’t start taking seven times more medication. What changed was that manufacturing — especially for generics and active pharmaceutical ingredients (APIs) — moved to cheaper countries and the domestic base quietly hollowed out.
Here’s what that looks like today:
- India fills roughly 61% of the generic oral solid doses taken in U.S. pharmacies.
- India itself buys up to 80% of its APIs from China.
- A 2024 GAO report found no manufacturing visibility for 63% of critical U.S. drugs.
- Around 22% of APIs in circulation have no confirmed country of origin.
- By early 2025, 270 drugs were on the FDA’s active shortage list — a record high.
Close to 60% of those shortages had been running for two years or more. Not a bad quarter. A pattern that’s been building for years while attention stayed on price negotiations.
One Storm Showed How Exposed the System Really Is
September 2024. Hurricane Helene flooded a Baxter International plant in North Carolina. That one site produced close to 60% of the country’s IV fluids. Hospitals started rationing bags within days. Elective procedures got pushed. Emergency imports needed federal fast-tracking just to keep critical care units stocked.
One facility. One storm. The whole country scrambling.
That was a domestic plant. The exposure gets worse when the problem originates overseas — in India or China — where U.S. regulators have no enforcement authority and very little real-time visibility into what’s happening on the ground.
Triggers that have caused real U.S. shortages in recent years include:
- API plants shut down after failing FDA inspections
- Port and logistics backlogs cutting off shipment timelines
- Chinese chemical suppliers going offline, stalling API production upstream
- Foreign export restrictions during periods of political or economic tension
Drug wholesale distributors take the hit when this happens. Phones start ringing from hospitals and pharmacies looking for product that isn’t there. If sourcing is locked into one or two suppliers and both go quiet at the same time, there’s no quick fix.
How Things Got to This Point
Offshoring made financial sense, and for a good stretch, nobody paid a visible price for it. Labor abroad was cheap. Building manufacturing capacity in India or China moved faster than navigating U.S. permitting. Domestic generic makers couldn’t match foreign prices, so they pulled back from API production and eventually left those markets entirely.
Patients got cheaper generics. Health systems saved on procurement. It looked like smart economics.
What got traded away quietly:
Traceability. If you don’t know where an API came from, you can’t assess contamination risk or respond meaningfully when something goes wrong.
Redundancy. Two or three overseas suppliers controlling a drug category means any single problem becomes a nationwide supply problem.
Domestic capacity. Once those manufacturing lines close, getting them back online costs tens of millions of dollars — money that doesn’t pencil out for a generic selling at pennies per tablet without outside support.
What Washington Is Actually Doing
The federal government has stopped treating this purely as a trade issue. In 2025, the administration kinda launched a Section 232 investigation about pharmaceutical imports — using the same old mechanism that showed up before, with steel, and even semiconductors tariffs. Then an executive order came in, pushing for building this kind of Strategic Active Pharmaceutical Ingredients Reserve, or SAPIR, basically. The goal was a six-month domestic stockpile of APIs across, roughly 26 critical drug categories, so it sounded straightforward, but yeah kinda.
Legislation in progress includes:
- Tax credits for companies that bring API manufacturing back to the U.S.
- Faster FDA review for new domestic production facilities
- Labeling rules that actually require disclosing API origin
- Long-term federal contracts to make domestic generic production worth the investment
Progress is slow. Some proposals may not survive the legislative process. But drug wholesale distributors paying attention know what direction this is heading. Single-source foreign dependency is getting more scrutiny, not less, and that’s going to reshape sourcing decisions over the next decade.
What Buyers Should Be Asking Their Distributors
When a shortage hits, the first call goes to the distributor. How that call goes depends on choices made long before the shortage showed up.
Questions worth asking any distribution partner:
- Where are your products sourced, and do you hold secondary suppliers for high-risk categories?
- How early does your team spot a tightening supply signal?
- Is every product DSCSA traceable regardless of where it originated?
- How much of your catalog comes from domestic or near-shore manufacturers?
These aren’t questions reserved for large health systems with dedicated procurement teams. Any pharmacy or provider managing essential medications should know the answers. Partnering with drug wholesale distributors who can respond clearly — and prove it — is one of the more practical hedges available right now.
Reshoring takes years. Policy change takes longer. But the distributor relationship is something that can change much sooner, and it matters more than most buyers realize until something goes wrong.
Drugzone Pharmaceuticals Inc.: Dependable Distribution You Can Count On
Drugzone Pharmaceuticals Inc. is a nationally licensed, NABP-accredited generic pharmaceutical distributor based in Nanuet, New York, licensed across all 50 states. Founded by a New York-licensed pharmacist, the leadership team carries over 80 years of combined experience in distribution, compliance, and healthcare.
Drugzone runs a 20,000 sq. ft. temperature-controlled facility, works with 75+ manufacturer partners, and stocks 2,000+ SKUs across human and animal health. Hospitals, LTC facilities, specialty clinics, compounding pharmacies, and veterinary providers count on them daily. As established drug wholesale distributors, Drugzone holds FDA registration, DSCSA 2025 compliance, and NABP accreditation — authentic, traceable product, delivered reliably.
Frequently Asked Questions
- Why does import dependency lead to drug shortages in the U.S.? Most generic APIs come from a small cluster of overseas suppliers. One inspection failure, one export restriction — and there’s no domestic fallback ready. That’s why a single overseas disruption can drag on for two or three years in U.S. pharmacies.
- Which drug types get hit hardest? Sterile injectables, oncology drugs, and older generics feel it most. The margins are too thin to draw domestic manufacturers back in, so supply stays heavily concentrated in foreign facilities. When those plants have problems, there’s rarely a quick domestic alternative.
- What can healthcare providers do to lower their shortage risk? Look hard at your distribution partner before a shortage starts. Multi-source procurement, active shortage monitoring, and full DSCSA traceability matter. Waiting until a medication is already backordered to ask these questions is usually too late.
- What do drug wholesale distributors actually do during a shortage?
Drug wholesale distributors tend to see supply tightening before their customers do. The good ones are already working alternatives before the shortage is officially declared. Distributors with wide manufacturer networks can reroute and substitute faster. Those with limited sourcing are mostly stuck waiting alongside their customers. That gap shows up clearly when supply gets tight.